Oncology News

Cipla's US unit has partnered with China's Qilu Pharmaceutical to license QL2107, a biosimilar of Merck's cancer drug Keytruda, for commercialization in the US,

Cipla has announced a partnership with China's Qilu Pharma to develop and commercialize a cancer biosimilar, reinforcing Cipla's focus on its oncology portfolio

Sun Pharma plans to extend Most Favored Nation (MFN) pricing to US state Medicaid programs, leveraging its strong position in dermatology and recent launches in

The FDA has approved Rasonque, a $39,800 once-daily pill by Revolution Medicines, for metastatic pancreatic adenocarcinoma, marking a significant breakthrough i

A new drug conjugate strategy has been developed that enables targeted payload release without cellular internalization, improving tumor specificity and efficac

Lord's Mark Industries is undertaking a strategic healthcare expansion and business demerger, focusing on advanced diagnostics, oncology, and medical devices, i

AstraZeneca's nerve drug Wainua failed a late-stage heart disease trial, causing investor concern and a slide in the company's share price. The company's future

Menarini Asia-Pacific and Pharmacosmos have formed a partnership to introduce Cosela®, a first-in-class oncology supportive care therapy, to patients across Asi

Lupin has acquired an 82.2% stake in Kaveri Therapeutics and licensed two oncology assets for $1.6 million, with Kaveri set to advance the oncology program thro

A persistent myth in India that biopsies spread cancer is causing many families to delay crucial diagnostic tests for lumps, leading to cancer progression. Expe